Tai, D. W.-M. (David W.-M.)

Author search.filters.isAuthorOfPublication.8152bd99-fdc4-44ed-8847-358ac659f6f2

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I/II study
    (ASCO, 2021) Kate-Kelley, R. (Robin); Sangro, B. (Bruno); Harris, W. (William); Ikeda, M. (Masafumi); Okusaka, T. (Takuji); Kang, Y.K. (Yoon-Koo); Qin, S. (Shukui); Tai, D. W.-M. (David W.-M.); Yeong Lim, H. (Ho); Yau, T. (Thomas); Yong, W.-P. (Wei-Peng); Cheng, A.L. (Ann-Lii); Gasbarrini, A. (Antonio); Damian, S. (Silvia); Bruix, J. (Jordi); Borad, M. (Mitesh); Bendell, J. (Johanna); Kim, T.Y. (Tae-You); Standifer, N. (Nathan); He, P. (Philip); Makowsky, M. (Mallory); Negro, A. (Alejandra); Kudo, M. (Masatoshi); Abou-Alfa, G.K. (Ghassan K.)
    This phase I/II study evaluated tremelimumab (anticytotoxic T-lymphocyte–associated antigen-4 monoclonal antibody) and durvalumab (antiprogrammed death ligand-1 monoclonal antibody) as monotherapies and in combination for patients with unresectable hepatocellular carcinoma (HCC), including a novel regimen featuring a single, priming dose of tremelimumab (ClinicalTrials.gov identifier: NCT02519348).